Approaches to correction of immune system disturbances in post-COVID patients

Cover Page

Cite item

Full Text

Abstract

SARS-CoV-2 virus can induce immune system disorders in post-COVID patients, which may persist for an extended period beyond the acute phase of the disease. Therefore, the search for immunocorrection approaches to address the detected disorders is a significant challenge in clinical immunology. This study aimed to investigate the impact of a synthetic peptide derived from the active center of GM-CSF on the immune system of patients with post-COVID immunopathological syndrome. A total of 21 patients who previously suffered with SARS-CoV-2 infection were included in the study. Flow cytometry was used to analyze various immune cell populations, including panleukocyte markers for gated lymphocytes (CD45+ and CD46+), T lymphocytes (CD3+), helper inducers (CD3+, CD4+), cytotoxic T lymphocytes (CD3+, CD8+), TNK cells (CD3+, CD56+), natural killer cells (CD3-, CD56+), B lymphocytes (CD3-, CD19+), activated helper cells (CD3+, CD4+, CD25+), and activated T lymphocytes (CD3+, HLA-DR). Moreover, IgA, IgM, IgG antibodies specific to SARS-CoV-2, phagocytosis and NBT activity of neutrophils, and complement fragments C1q, C3a, and C5a were assessed. The results demonstrated that topical application of the synthetic peptide derived from the active center of GM-CSF (Acegram-spray) upon mucous membranes significantly influenced the functional bactericidal activity of neutrophils (NBT-activity), increased the percentage of T helper cells, and elevated the C3a complement fragment. These findings indicate that the synthetic peptide primarily affects innate immunity factors. However, no significant differences were observed in other immune system parameters. Therefore, the development of therapeutic approaches for post-COVID patients with impaired immune systems may require a search for additional immunomodulators that target T, B, and NK cells. Further research is needed to explore the effects of various immunomodulators on the immune system of post-COVID patients.

About the authors

Maria A. Dobrynina

Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences; Federal A. Burnazyan Medical Biophysical Research Center; Federal Research Institute of Viral Infections “VIROM”

Author for correspondence.
Email: mzurochka@mail.ru

PhD (Medicine), Research Associate, Laboratory of Immunopathophysiology, Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences; Senior Research Associate, Laboratory of Transmissible Viral Diseases, Federal Research Institute of Viral Infections “VIROM”, Yekaterinburg; Associate Professor, Department of Therapy of the University of Innovation and Continuing Education, Federal A. Burnazyan Medical Biophysical Research Center

Russian Federation, Yekaterinburg; Moscow; Yekaterinburg

A. V. Zurochka

Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences; South Ural State University (National Research University)

Email: av_zurochka@mail.ru

PhD, MD (Medicine), Professor, Honored Worker of Science of the Russian Federation, Leading Research Associate, Laboratory of Immunopathophysiology, Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences, Yekaterinburg; Head, Laboratory of Immunobiotechnology of the Russian-Chinese Center, South Ural State University (National Research University)

Russian Federation, Yekaterinburg; Chelyabinsk

V. A. Zurochka

Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences; South Ural State University (National Research University)

Email: v_zurochka@mail.ru

PhD, MD (Medicine), Senior Research Associate, Laboratory of Immunopathophysiology, Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences, Yekaterinburg; Senior Research Associate, Laboratory of Immunobiotechnology of the Russian-Chinese Center, South Ural State University (National Research University)

Russian Federation, Yekaterinburg; Chelyabinsk

L. V. Ryabova

South Ural State Medical University

Email: lianarabowa@rambler.ru

PhD, MD (Medicine), Associate Professor, Professor, Department of Life Safety, Disaster Medicine, Emergency Medicine, South Ural State Medical University

Russian Federation, Chelyabinsk

A. P. Sarapultsev

Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences; South Ural State University (National Research University)

Email: a.sarapultsev@gmail.com

PhD, MD (Biology), Leading Research Associate, Head, Laboratory of Immunopathophysiology, Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences, Yekaterinburg; Director, Russian-Chinese Center, South Ural State University (National Research University)

Russian Federation, Yekaterinburg; Chelyabinsk

References

  1. Добрынина М.А., Зурочка А.В., Комелькова М.В., Ло Ш. Исследование нарушения натуральных киллеров у пациентов, перенесших Сovid-19 // Российский иммунологический журнал 2022. Т. 25, № 2. C. 161-166. [Dobrynina M.A., Zurochka A.V., Komelkova M.V., Lo Sh. Impairment of natural killer populations in the patients recovered from COVID-19. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2022, Vol. 25, no. 2, pp. 161-166. (In Russ.)] doi: 10.46235/1028-7221-1132-ION.
  2. Добрынина М.А., Зурочка А.В., Комелькова М.В., Ло Ш., Зурочка В.А., Ху Д., Рябова Л.В., Сарапульцев А.П. Исследование экспрессии CD45+ и CD46+ на субпопуляциях лимфоцитов периферической крови постковидных пациентов // Российский иммунологический журнал, 2022. Т. 25, № 4. C. 431-436. [Dobrynina M.A., Zurochka A.V., Komelkova M.V., Lo Sh., Zurochka V.A., Khu D., Ryabova L.V., Sarapultsev A.P. Study of CD45+ and CD46+ expression on subpopulations of peripheral blood lymphocytes in post-COVID patients. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2022, Vol. 25, no. 4, pp. 431-436. (In Russ.)] doi: 10.46235/1028-7221-1160-SOC.
  3. Добрынина М.А., Зурочка А.В., Комелькова М.В., Luo S., Семенова Д.А. Оценка взаимосвязи нарушения цитотоксических Т-лимфоцитов с другими компартментами иммунной системы у постковидных пациентов // Вестник уральской медицинской академической науки, 2022. Т. 19, № 3. C. 294-303. [Dobrynina M.A., Zurochka A.V., Komelkova M.V., Luo S., Semenova D.A. Evaluation of the relationship between the violation of cytotoxic T-lymphocytes and other compartments of the immune system in post-COVID patients. Vestnik uralskoy meditsinskoy akademicheskoy nauki = Bulletin of the Ural Medical Academic Science, 2022, Vol. 19, no. 3, pp. 294-303. (In Russ.)]
  4. Зурочка А.В., Гриценко В.А., Зурочка В.А., Добрынина М.А., Черешнев В.А. Гранулоцитарно-макрофагальный колониестимулирующий фактор (ГМ-КСФ) и его синтетические аналоги: иммунологические эффекты и клиническое применение. Екатеринбург: УрО РАН, 2021. 288 с. [Zurochka A.V., Gritsenko V.A. Zurochka V.A., Dobrynina M.A., Chereshnev V.A. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and its synthetic analogues: immunological effects and clinical applications]. Yekaterinburg: UB RAS, 2021. 288 p.
  5. Забков О.И., Зурочка В.А., Добрынина М.А., Гриценко В.А., Зурочка А.В. Клинико-диагностические критерии эффективности комплексной этиопатогенетической терапии хронической Эпштейна–Барр вирусной инфекции // Бюллетень Оренбургского научного центра УрО РАН, 2018. № 3. 12 c. [Zabkov O.I., Zurochka V.A., Dobrynina M.A., Gritsenko V.A., Zurochka A.V. Clinical and diagnostic criteria for the effectiveness of complex etiopathogenetic therapy for chronic Epstein-Barr virus infection. Byulleten Orenburgskogo nauchnogo tsentra UrO RAN = Bulletin of the Orenburg Scientific Center of the Ural Branch of the Russian Academy of Sciences, 2018, no. 3, 12 p. (In Russ.)]
  6. Зурочка В.А., Забков О.И., Добрынина М.А., Гриценко В.А., Давыдова Е.В., Чукичев А.В., Забокрицкий Н.А., Сарапульцев А.П., Зурочка А.В. Иммунологические критерии эффективности комплексной этиопатогенетической терапии у больных хронической вирусной инфекцией, ассоциированной с вирусом Эпштейна–Барр // Инфекция и иммунитет, 2020. Т. 10, № 2. С. 338-346. [Zurochka V.A., Zabkov O.I., Dobrynina M.A., Gritsenko V.A., Davydova E.V., Chukichev A.V., Zabokritsky N.A., Sarapultsev A.P., Zurochka A.V. Immunological criteria for the effectiveness of complex etiopathogenetic therapy in patients with chronic viral infection associated with the Epstein-Barr virus. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2020, Vol. 10, no. 2, pp. 338-346. (In Russ.)] doi: 10.15789/2220-7619-CDC-1141.
  7. Зурочка А.В., Зурочка В.А., Добрынина М.А., Фомина Л.О., Забков О.И., Гриценко В.А. Иммунобиологические свойства синтетических аналогов гранулоцитарно-макрофагального колониестимулирующего фактора (ГМ-КСФ) // Российский иммунологический журнал, 2019. Vol. 13 (22), no. 2, pp. 778-780. [Zurochka A.V., Zurochka V.A., Dobrynina M.A., Fomina L.O., Zabkov O.I., Gritsenko V.A. Immunobiological properties of synthetic analogs of granulocyte-macrophage colony-stimulating factor (GM-CSF). Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2019, Vol. 13 (22), no. 2, pp. 778-780. (In Russ.)]. doi: 10.31857/S102872210006701-6.
  8. Зурочка А.В., Хайдуков С.В., Кудрявцев И.В., Черешнев В.А. Проточная цитометрия в биомедицинских исследованиях. Екатеринбург: РИО УрО РАН, 2018. 720 с. [Zurochka A.V. Khaidukov S.V., Kudryavtsev I.V., Chereshnev V.A. Flow cytometry in biomedical research]. Ekaterinburg: RIO Ural Branch of the Russian Academy of Sciences, 2018. 720 p.
  9. Хайдуков С.В., Байдун Л.А., Зурочка А.В., Тотолян А.А. Стандартизованная технология «Исследование субпопуляционного состава лимфоцитов периферической крови с применением проточных цитофлюориметров-анализаторов» // Российский иммунологический журнал, 2014. Т. 8 (17), № 4. С. 974-992. [Khaydukov S.V., Baidun L.A., Zurochka A.V., Totolyan A.A. Standardized technology “Study of the subpopulation composition of peripheral blood lymphocytes using flow cytofluorometer-analyzers”. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2014, Vol. 8 (17), no. 4, pp. 974-992. (In Russ.)]
  10. Dobrynina M.A., Ibragimov R.V., Kritsky I.S., Verkhovskaya M.D., Mosunov A.A., Sarapultsev G.P., Zurochka A.V., Zurochka V.A., Sarapultsev A.P., Komelkova M.V., Ryabova L.V., Praskurnichiy E.A. Post-COVID immunopatologysyndrome: characteristics of phenotypical changes in the immune system in post-COVID patients. Medical Immunology (Russia) 2023, Vol. 25, no. 4, pp. 791-796. doi: 10.15789/1563-0625-PCI-2707.
  11. Gusev E., Sarapultsev A., Solomatina L., Chereshnev V. SARS-CoV-2-specific immune response and the pathogenesis of COVID-19. Int. J. Mol. Sci., 2022, Vol. 23, no. 3, 1716. doi: 10.3390/ijms23031716.
  12. Jouan Y., Guillon A., Gonzalez L., Perez Y., Boisseau C., Ehrmann S,. Ferreira M., Daix T., Jeannet R., François B., Dequin P.F., Si-Tahar M., Baranek T., Paget C. Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients. J. Exp. Med., 2020, Vol. 217, no. 12, e20200872. doi: 10.1084/jem.20200872.
  13. Le Friec G., Sheppard D., Whiteman P., Karsten C.M., Shamoun S.A., Laing A., Bugeon L., Dallman M.J., Melchionna T., Chillakuri C., Smith R.A., Drouet C., Couzi L., Fremeaux-Bacchi V., Köhl J., Waddington S.N., McDonnell J.M., Baker A., Handford P.A., Lea S.M., Kemper C. The CD46-Jagged1 interaction is critical for human TH1 immunity. Nat. Immunol., 2012, Vol. 13, no. 12, pp. 1213-1221.
  14. Masselli E., Vaccarezza M., Carubbi C., Pozzi G., Presta V., Mirandola P., Vitale M. NK cells: A double edge sword against SARS-CoV-2. Adv. Biol. Regul., 2020, Vol. 77, 100737. doi: 10.1016/j.jbior.2020.100737.
  15. Verdecchia P., Cavallini C., Spanevello A., Angelim F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur. J. Intern. Med., 2020, Vol. 76, pp. 14-20.

Copyright (c) 2023 Dobrynina M.A., Zurochka A.V., Zurochka V.A., Ryabova L.V., Sarapultsev A.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies